PetCaseFinder

Peer-reviewed veterinary case report

Protein marker PGP 9.5 found in dog skin T-cell lymphoma cells

By Ramos-Vara, J A & Miller, M A·Published in Veterinary pathology·2007·Purdue University, United States·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Immunohistochemical detection of protein gene product 9.5 (PGP 9.5) in canine epitheliotropic T-cell lymphoma (mycosis fungoides).

Species:
dog
LymphomaSkin & coatDogs

Plain-English summary

A dog with skin cancer called epitheliotropic T-cell lymphoma (mycosis fungoides) was examined for a specific protein (PGP 9.5) that is usually linked to nerve tissues. In a study of 14 similar cases, researchers found that 8 of the tumors showed this protein, but it didn't help predict how the cancer would behave or affect the dog's health. The presence of PGP 9.5 in these tumors suggests it might not be a reliable marker for diagnosing skin cancers in dogs. Treatment outcomes varied, but the study did not provide specific details on recovery or treatment success.

People also search for: dog skin cancer symptoms · mycosis fungoides treatment in dogs · PGP 9.5 in canine lymphoma

Abstract

Protein gene product 9.5 (PGP 9.5), a ubiquitin COOH-terminal hydrolase initially considered specific for neural and neuroendocrine tissues, is expressed in a variety of epithelial and mesenchymal tumors. During immunohistochemical evaluation of a cutaneous epitheliotropic T-cell lymphoma (mycosis fungoides [MF]) in a dog, strong reactivity for PGP 9.5 was observed. This unexpected result prompted us to examine PGP 9.5 immunoreactivity in 13 additional cases of canine mycosis fungoides. All tumors were confirmed as T-cell epitheliotropic lymphoma by histopathology and immunohistochemistry for CD3. Eight of 14 cases were positive for PGP 9.5, with reactivity mainly in the cytoplasm and less commonly in the nucleus. One case had strong reactivity in the cell membrane, sometimes with concurrent paranuclear staining. Immunoreactivity did not correlate with location (epidermal, dermal, and adnexal) of tumor cells. Disease outcome did not vary between PGP 9.5-positive and negative tumors. Although PGP 9.5 immunoreactivity in MF did not predict tumor behavior in these dogs, it has had prognostic value in certain human carcinomas. This unexpected staining of lymphocytes in mycosis fungoides with an antibody to PGP 9.5 demonstrates its presence in nonneuroendocrine tumors and precludes its use as the sole diagnostic marker in discrete cell tumors in the skin.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17197626/